Position	Ref_Base	Var_Base	Clinically_Flagged	Valid_Reads	Reference_Reads	Variant_Reads
chr2:215657138	A	G	BARD1  c.247T>C  p.C83R Disrupts RING finger  breast/ovca risk	166	166	0
chr2:215661788	C	T	BARD1 c.212G>A  p.C71Y Disrupts RING finger  breast/ovca risk	679	678	0
chr1:115256528	T	G	NRAS p.Q61H Used to select MEK inhibitors in melanoma.  Probable resistance to EGFR inhibitors	799	799	0
chr1:115256528	T	A	NRAS Q61H Used to select MEK inhibitors in melanoma.  Probable resistance to EGFR inhibitors	799	799	0
chr1:115256529	T	A	NRAS Q61L  Used to select MEK inhibitors in melanoma.  Probable resistance to EGFR inhibitors	805	805	0
chr1:115256529	T	C	NRAS Q61R  Used to select MEK inhibitors in melanoma.  Probable resistance to EGFR inhibitors	805	805	0
chr1:115256530	G	T	NRAS Q61K Used to select MEK inhibitors in melanoma.  Probable resistance to EGFR inhibitors	808	807	1
chr1:115258744	C	T	NRAS G13D  Used to select MEK inhibitors in melanoma.  Probable resistance to EGFR inhibitors	1270	1270	0
chr1:115258744	C	A	NRAS G13V  Used to select MEK inhibitors in melanoma.  Probable resistance to EGFR inhibitors	1270	1270	0
chr1:115258745	C	G	NRAS G13R  Used to select MEK inhibitors in melanoma.  Probable resistance to EGFR inhibitors	1274	1274	0
chr1:115258747	C	G	NRAS G12A  Used to select MEK inhibitors in melanoma.  Probable resistance to EGFR inhibitors	1288	1288	0
chr1:115258747	C	T	NRAS G12D  Used to select MEK inhibitors in melanoma.  Probable resistance to EGFR inhibitors	1288	1288	0
chr1:115258747	C	A	NRAS G12V  Used to select MEK inhibitors in melanoma.  Probable resistance to EGFR inhibitors	1288	1288	0
chr1:115258748	C	A	NRAS G12C  Used to select MEK inhibitors in melanoma.  Probable resistance to EGFR inhibitors	1288	1288	0
chr1:115258748	C	T	NRAS G12S  Used to select MEK inhibitors in melanoma.  Probable resistance to EGFR inhibitors	1288	1288	0
chr1:162724541	C	A	DDR2 R105S Reported in lung cancer	786	785	1
chr1:162740165	A	G	DDR2 N456S Reported in lung cancer	1142	1142	0
chr1:162746056	G	T	DDR2 A727S Unknown significance.  Seen once in a non small cell lung cancer at UW	1090	1088	1
chr1:43815008	T	A	MPL W515K  diagnosis of ET and Primary myelofibrosis when ocurring with G>A chr1:43815009	486	484	0
chr1:43815009	G	A	MPL W515K  diagnosis of ET and Primary myelofibrosis when ocurring with T>A chr1:43815008	484	484	0
chr1:43815009	G	T	MPL W515L  diagnosis of ET and Primary myelofibrosis	484	484	0
chr1:45797228	C	T	MUTYH pathogenic recessive germline variant p.G396D commonly known as p.G382D	308	308	0
chr1:45798115	C	A	MUTYH p.V246F also known as V232F.  Likely pathogenic recessive allele observed in MAP patients and functionally characterized 15673720.	712	711	1
chr1:45798475	T	C	MUTYH p.Y179C pathogenic recessive allele	976	975	1
chr1:97915614	C	T	DPYD IVS14+1 G>A germline.  5-FU CONTRAINDICATED due to toxicity	1010	1008	2
chr10:123274794	T	C	FGFR2 p.Y376C known hotspot mutation in endometrial cancer	813	813	0
chr10:123279677	G	C	FGFR2 p.S252F activating mutation 17525745	391	391	0
chr11:108199929	T	G	ATM c.7271T>G  p.V2424G Orkney Island allele  well established breast cancer risk  9463314 and unpublished data	476	475	1
chr12:12022722-12022731	TCTGATCCTG	-	ETV6 del seen once at UW	660	660	0
chr12:133244199	T	C	POLE T737A Alaskan native allele	941	939	1
chr12:133250250	C	G	POLE p.L424V pathogenic germline mutation associated with CRC and endometiral cancer risk 23263490 and 23528559	711	711	0
chr12:133250250	G	C	POLE p.L424V pathogenic germline mutation associated with CRC and endometiral cancer risk 23263490 and 23528559	711	711	0
chr12:25378562	C	T	KRAS A146T probable resistance to EGFR inhibitors in colon cancer	759	758	0
chr12:25378647	T	A	KRAS K117N probable resistance to EGFR inhibitors in colon cancer	782	782	0
chr12:25378647	T	G	KRAS K117N probable resistance to EGFR inhibitors in colon cancer	782	782	0
chr12:25380275	T	G	KRAS Q61H Probable resistance to EGFR inhibitors in colon cancer	667	666	0
chr12:25380275	T	A	KRAS Q61H Probable resistance to EGFR inhibitors in colon cancer	667	666	0
chr12:25380276	T	A	KRAS Q61L Probable resistance to EGFR inhibitors in colon cancer	665	664	0
chr12:25380276	T	G	KRAS Q61P Probable resistance to EGFR inhibitors in colon cancer	665	664	0
chr12:25380276	T	C	KRAS Q61R Probable resistance to EGFR inhibitors in colon cancer	665	664	0
chr12:25380277	G	T	KRAS Q61K Probable resistance to EGFR inhibitors in colon cancer	664	664	0
chr12:25380283	C	T	KRAS A59T unknown response to EGFR inhibtiors but reported in colorectal cancer 20619739	661	661	0
chr12:25398281	C	T	KRAS G13D  possible resistance to EGFR inhibitors. See literature.	593	593	0
chr12:25398281	C	A	KRAS G13V  resistance to EGFR inhibitors in colon cancer	593	593	0
chr12:25398282	C	A	KRAS G13C  resistance to EGFR inhibitors in colon cancer	592	592	0
chr12:25398282	C	T	KRAS G13S  resistance to EGFR inhibitors in colon cancer	592	592	0
chr12:25398284	C	G	KRAS G12A  resistance to EGFR inhibitors in colon cancer	582	581	0
chr12:25398284	C	T	KRAS G12D  resistance to EGFR inhibitors in colon cancer	582	581	0
chr12:25398284	C	A	KRAS G12V  resistance to EGFR inhibitors in colon cancer	582	581	1
chr12:25398285	C	A	KRAS G12C  resistance to EGFR inhibitors in colon cancer	583	583	0
chr12:25398285	C	G	KRAS G12R  resistance to EGFR inhibitors in colon cancer	583	583	0
chr12:25398285	C	T	KRAS G12S  resistance to EGFR inhibitors in colon cancer	583	583	0
chr13:28592641	T	A	FLT3 D835V  TKD mutation	1151	1150	1
chr13:28592642	C	G	FLT3 D835H  TKD mutation	1156	1156	0
chr13:28592642	C	T	FLT3 D835N  TKD mutation	1156	1156	0
chr13:28592642	C	A	FLT3 D835Y  TKD mutation	1156	1156	0
chr13:32900625	T	C	Germline Previously reported as VUS by Myriad IVS6-11T>C	698	698	0
chr13:32914438	T	-	BRCA2 6174delT AJ founder mutation	936	934	0
chr13:32919384	T	G	BRCA2 IVS12 7164 (+594) c.6937(+594) T>G mRNA ins [IVS12(+495 to +589)] (Silvia)	0	0	0
chr13:32936674	C	T	BRCA2 c.7820 C>T  p.T2607I mRNA skip ex17 and ex17-18 (Silvia)	420	420	0
chr13:32936733	A	T	BRCA2 c.7879 A>T  p.I2627F mRNA skip ex 17-18 (Silvia)	571	571	0
chr13:32937327	A	T	BRCA2 c.7988 A>T  p.E2663V mRNA skip ex 18 (Silvia)	575	574	0
chr13:32937348	C	T	BRCA2 c.8009 C>T  p.S2670L mRNA skip ex 18 (Silvia)	661	659	0
chr13:32937506	G	C	BRCA2 C.8167  p.D2723H Disrupts nuclear export signal  24013206	1081	1081	0
chr13:32937506	G	C	BRCA2 p.D2723H pathogenic PMID 24013206 and 15290653	1081	1081	0
chr13:32937507	A	G	BRCA2 c.8168 A>G  p.D2723G mRNA 8396 del 164 (Silvia)	1087	1086	1
chr14:105246551	C	T	AKT1 p.E17K is a recurrent activating mutation in many cancers.  It may be targetable by AKT inhibitors	446	445	1
chr15:43762078-43762083	GGGATA	-	TP53BP1 c.1347_1352del benign nonframeshift ins	0	0	0
chr15:66727455	G	T	MEK1 K57N Constituitive activation. In vitro response to MEK inhibitor AZD6244 and in vitro resistance to TKIs.	784	784	0
chr15:90631934	C	T	IDH2 R140Q  prognosis in AML	551	551	0
chr15:90631935	G	A	IDH2 p.R140W PROGNOSIS in AML	538	538	0
chr16:2124321	C	A	TSC2 L826M Germline probably benign. Annotated as rare polymorphism in TSC project db	332	332	0
chr16:68845646	G	A	CDH1 p.A298T germline VUS vs likely deleterious.  Reported in one family with diffuse gastric cancer and shown to be damaging to E-cadherin in an in vitro assay 15235021.	973	973	0
chr16:68862107	G	A	CDH1  c.2195G>A  p. R732Q Lobular breast cancer risk 17545690	1129	1129	0
chr17:37880981	-	GCATACGTGATG	ERBB2 (HER2) exon 20 insertion probably senstizies to dual EGFR HER2 TKIs in NSCLC	533	533	0
chr17:37881000	G	T	The p.V777L mutation lies within the kinase domain and has been reported in gastric colorectal and breast cancers (Lee 2006). Recent preclinical work has demonstrated that breast cancer cell lines harboring the p.V777L mutation were sensitive to trastuzumab lapatinib and neratinib (Bose 2013).	568	568	0
chr17:37881002	-	GGCTCCCCA	ERBB2 (HER2) exon 20 insertion probably senstizies to dual EGFR HER2 TKIs in NSCLC	586	586	0
chr17:41203121	A	G	BRCA1 c.5291 T>C  p.L1764P Definitely pathogenic per IARC	588	588	0
chr17:41209079	-	G	BRCA1 5382insC AJ founder mutation	1037	1036	0
chr17:41209139	A	C	BRCA1 c.5207 T>G  p.V1736G mRNA skip ex 20  reduced mutant message (Silvia)	978	978	0
chr17:41219627	G	A	BRCA1 c.5072 C>T  p.T1691I mRNA skip ex 17 (Silvia)	649	649	0
chr17:41234558	A	G	BRCA1 c.4220 T>C  p.L1407P Disrupts coiled-coil structure	557	556	0
chr17:41243509	T	C	BRCA1 161x in BIC probably not important	875	875	0
chr17:41267746	C	A	BRCA1 c.131 G>T  p.C44F Loss of ubiquitin ligase activity	491	490	0
chr17:41276045-41276046	CT	-	BRCA1 185delAG AJ founder mutation	406	406	0
chr17:46805705	C	T	HOXB13 G84E prostate cancer risk allele 23518396 23064873	0	0	0
chr17:56774077	A	G	RAD51C  c.428A>G  p.Q143R. Ovca risk (Swisher) and 22451500	775	774	0
chr17:7578406	C	T	TP53 R175H well described deleterious germline and somatic mutation	477	477	0
chr19:3118942	A	T	GNA11 Q209L activating mutation in 34% of uveal melanomas.  Usually exclusive of other drivers such as BRAF KIT and NRAS	483	483	0
chr19:33792731	-	GCGGGT	CEBPA known benign germline polymorphism in TAD2 domain PMID: 17851556 	60	60	0
chr19:45854919	T	G	ERCC2 rs13181T>G.  G allele worse response to oxaliplatin therapy in colorectal cancer 21278243 	583	312	271
chr19:45923653	A	G	ERCC1 rs11615T>C.  T allele worse response to oxaliplatin therapy in colorectal cancer 21278243 	4	3	1
chr19:50909713	G	A	POLD1 p.S478N pathogenic germline mutation associated with CRC and endometiral cancer risk 23263490 and 23528559	426	426	0
chr19:50909713	C	T	POLD1 p.S478N pathogenic germline mutation associated with CRC and endometiral cancer risk 23263490 and 23528559	426	426	0
chr2:209113112	C	T	IDH1 R132H  glioma diagnosis  prognosis in AML	788	788	0
chr2:209113112	C	A	IDH1 R132L  glioma diagnosis  prognosis in AML	788	788	0
chr2:209113113	G	A	IDH1 R132C  glioma diagnosis  prognosis in AML	800	799	0
chr2:209113113	G	C	IDH1 R132G  glioma diagnosis  prognosis in AML	800	799	0
chr2:215661841	A	C	BARD1  c.159T>G  p.C53W Disrupts RING finger  breast/ovca risk	703	702	0
chr2:25457191	C	T	DNMT3A R899H  unclear significance  look up	958	958	0
chr2:25457242	C	T	DNMT3A R882H  prognosis and treatment in AML	832	830	0
chr2:25457243	G	A	DNMT3A R882C  prognosis and treatment in AML	829	829	0
chr2:25457243	G	T	DNMT3A R882S  prognosis and treatment in AML	829	829	0
chr2:25463541	G	C	DNMT3A S714C  unclear significance but seen in multiple AML patients  look up	607	606	0
chr2:25467437	G	A	DNMT3A L547F  unclear significance  look up	664	663	0
chr2:25467449	C	A	DNMT3A G543C  probably relevant for AML	691	690	1
chr2:47641560	A	T	MSH2 c.942+3 A>T pathogenic Lynch mutation within noisy microsatellite tract.  Can be missed by variant callers.	263	180	1
chr2:47693788	A	T	MSH2 NM_000251:exon10:c.1511-9A>T Reported 26 times in InSight and benign	910	909	0
chr2:48026168	A	G	MSH6 Q349R Germline VUS	1705	1705	0
chr2:48027269-48027272	CAGT	-	MSH6 deletion seen twice TIDB1232	1347	1346	0
chr2:48027755	T	C	MSH6 V878A 41 hits in Insight with conflicting literature (we have reported as VUS)	1382	1381	0
chr2:48030646	C	G	MSH6 P1087R Germline probably benign PMID 12019211	1558	1557	0
chr20:31022441	-	G	ASXL1 Frameshift seen in OPX-0003T	386	381	1
chr20:57484420	C	T	GNAS p.R201C is an activating mutation in fibrous dsyplasia and other neoplasms.  May be germline or somatic.  Germline associated McCune-Albright syndrome	1191	1190	1
chr20:57484421	G	A	GNAS p.R201H is an activating mutation in fibrous dsyplasia and other neoplasms.  May be germline or somatic.  Germline associated McCune-Albright syndrome	1197	1197	0
chr22:29091207	G	A	CHEK2  p.S428F	699	699	0
chr22:29091857	G	-	CHEK2 1100delC~2-3 fold increased breast cancer risk	504	503	0
chr22:29121058	C	T	CHEK2  p.G167R	895	893	0
chr22:29121077	T	C	CHEK2  p.I160M	900	900	0
chr22:29121087	A	G	CHEK2 I157T 1.5 fold increase in breast cancer risk 1.7 fold increase in colon cancer risk	889	888	1
chr22:29121242	G	A	CHEK2  p.R145W 	1051	1047	2
chr22:29121247	T	C	CHEK2  p.H143R	1041	1036	0
chr22:29130450-29130464	TCCTCAGGTTCTTGG	-	CHEK2 benign in frame deletion	582	581	0
chr22:29130520	C	T	"CHEK2 p.E64K VUS.   This variant has been reported before at least once and was shown to partially reduce CHEK2 protein kinase activity (Wu 2006).  In a different functional assay system (Roeb 2012) the CHEK2 p.E64K variant was also shown to impact CHEK2 protein function (Mary Claire King, personal communication).  "	639	639	0
chr3:178921553	T	A	PIK3CA p.N345K a known activating mutation	448	448	0
chr3:178927980	T	C	PIK3CA (p.C420R) - Activating mutation demonstrated in vitro (PMID 15647370)	532	532	0
chr3:178936082	G	A	PIK3CA E542K recurrent mutation.  Possible increased response to PI3K inhibitors	479	478	0
chr3:178936091	G	A	PIK3CA E545K Activating mutation found in diverse cancers.  Seen in GB-2T lung cancer	472	472	0
chr3:178938934	G	A	PIK3CA p.E726K recurrent hotspot	587	586	1
chr3:178952084	C	T	PIK3CA H1047Y is an activating mutation	770	770	0
chr3:178952085	A	T	PIK3CA H1047L Activating PIK3CA mutation.	770	769	0
chr3:178952085	A	G	PIK3CA H1047R Very common activating PIK3CA mutation.  Pre-clinical data suggests response to PI3K inhibitors	770	769	1
chr3:37034946	G	A	MLH1 c.-93G>A promoter polymporphism is associated with sporadic MLH1 loss and MSI-H but not with increased cancer risk	1611	877	734
chr3:37038192	G	A	MLH1 p.G67R - known pathogenic mutation observed in LMG1169 (TIDB 1952) and LMG-1836 (TIDB 2342)	1532	1532	0
chr3:37067306	G	A	MLH1 S406N Germline LIKELY BENIGN Class II variant	1236	1233	2
chr3:41266113	C	T	CTNNB1 p.S37F Common activating Beta catenin mutation	828	828	0
chr3:41266113	C	A	CTNNB1 p.S37Y Common activating Beta catenin mutation	828	828	0
chr3:41266137	C	T	CTNNB1 p.S45F Common activating Beta catenin mutation	804	804	0
chr3:41266137	C	A	CTNNB1 p.S45Y Common activating Beta catenin mutation	804	804	0
chr3:52442072	T	C	T93A new splice acceptor in RCC and breast cancer 23684012	380	380	0
chr3:52442072	T	C	BAP1 T93A renal cell carcinoma risk	380	380	0
chr4:55152093	A	T	PDGFRA D842V treatment responses in GIST	924	923	1
chr4:55593589-55593609	TGTATGAAGTACAGTGGAAGG	-	KIT 21bp exon 11 del response to imitanib in GIST	972	972	0
chr4:55593590-55593607	GTATGAAGTACAGTGGAA	-	KIT p.552_558del exon 11 imatinib sensitivity in GIST	977	977	0
chr4:55593601-55593615	AGTGGAAGGTTGTTG	-	KIT p.556_561del exon 11 imatinib sensitivity in GIST	999	998	0
chr4:55594221	A	G	K642E  predicts sensitivity to imatinib in melanoma	1061	1059	0
chr4:55599340	T	A	KIT p.N822K Recurrent Exon 17 Mutation in AML	851	851	0
chr4:55955969	C	T	KDR p.A1065T probably activating mutation.  In vitro evidence of response to VEGFR inhibitors PMID 19723655	866	866	0
chr4:84383770	C	T	 FAM175A/ABRAXAS c.1082G>A  p.R361Q Damaging to NLS  breast cancer risk 22357538	1121	1120	0
chr5:112115546	G	A	APC:c.532-941G>A GERMLINE probably pathogenic splice 22431159 	0	0	0
chr5:112158419	C	T	APC:c.1408+731C>T GERMLINE probably pathogenic splice 22431159 	0	0	0
chr5:112158423	A	T	APC:c.1408+735A>T GERMLINE probably pathogenic splice 22431159 	0	0	0
chr5:112173250	G	A	APC c.1959 G to A is probably a benign silent germline variant Aretz et al 15459959	488	488	0
chr5:112175211	T	A	APC I1307K Jewish APC allele pathogenic germline low penetrance colon cancer risk 11001924	946	945	1
chr5:170837543	-	TCTG	NPM1 c.772_773insTCTG  prognosis in AML	280	278	0
chr5:170837544	-	CTGC	NPM1c.773_774insCTGC  prognosis in AML	281	281	0
chr5:170837545	-	TGCA	NPM1 c.861_862insTGCA good prognosis in AML	285	283	0
chr5:67591118-67591135	ATCCAGCTGAGAAAGACG	-	PIK3R1 in frame deletion first seen by us in KA2T breast cancer.	826	825	0
chr7:140453134	T	C	BRAF K601E is probably an activating mutation	683	683	0
chr7:140453135	C	T	BRAF V600E variant probable  check position chr7:140453136	683	683	0
chr7:140453136	A	T	BRAF V600E common T>A sensitizes to BRAF inhibitors	681	680	0
chr7:140453137	C	T	BRAF V600K probable  check position chr7:140453136	681	681	0
chr7:140481393	A	C	BRAF A472S reported once in endometrial ca unclear significance 16144912	1227	1226	1
chr7:140481402	C	A	BRAF G469V highly conserved GXGXXG motif of the kinase domain. G469A in my cancer genome 	1269	1269	0
chr7:55241677	G	A	EGFR E709K probably sensitizes to TKIs	783	783	0
chr7:55241678	A	C	EGFR E709A probably sensitizes to TKIs	776	775	0
chr7:55241678	A	T	EGFR E709V probably sensitizes to TKIs	776	775	0
chr7:55241707	G	T	EGFR G719C probably sensitizes to TKIs	684	684	0
chr7:55241707	G	A	EGFR G719S probably sensitizes to TKIs	684	684	0
chr7:55241708	G	C	EGFR G719A probably sensitizes to TKIs	677	677	0
chr7:55242465-55242479	GGAATTAAGAGAAGC	-	EGFR exon 19 p.745_750del sensitizes to TKIs	877	876	0
chr7:55242466-55242480	GAATTAAGAGAAGCA	-	EGFR p.746_750del (exon 19 del) Sensitizes to TKIs (seen in GB-6T)	885	885	0
chr7:55242470-55242487	TAAGAGAAGCAACATCTC	-	EGFR p.747_753del sensitizes to TKIs	899	898	0
chr7:55248998	-	TGGCCAGCG	EGFR exon 20 insertion Lack of Response to TKIs (seen in OPX-0002T)	360	359	0
chr7:55249005	G	T	EGFR p.S768I probably sensitizes to TKIs	366	366	0
chr7:55249071	C	T	EGFR T790M resistance to TKIs	550	550	0
chr7:55259515	T	G	EGFR L858R sensitizes to TKIs	773	772	1
chr7:55259524	T	A	EGFR L861Q probably sensitizes to TKIs	769	767	0
chr7:6045549	C	A	PMS2 p.S46I known pathogenic germline variant	686	686	0
chr8:90983442-90983446	TTTGT	-	Slavic founder allele >2 fold risk for breast cancer.  Correct HGVS: NM_002485.4:c.657_661del p.(Lys219Asnfs*16)	338	338	0
chr8:90983460	G	A	NBN p.R215W germline.  This variant should go on a report because some groups report as pathogenic and associated with increased breast cancer risk.  We feel it is likely benign based on similar frequency in cases and controls. 	318	318	0
chr9:101594229	G	A	GALNT12 p.D303N Germline Colon Cancer Risk Allele	0	0	0
chr9:133738363	G	A	ABL1 E255K Imatinib resistance in CML	620	620	0
chr9:133748288	T	A	ABL1 F317I dasatinib resistance in cell culture models	388	386	0
chr9:133748288	T	C	ABL1 F317L imatinib- and dasatinib-resistance in CML	388	386	1
chr9:133750356	A	C	ABL1 H396P imatinib- and dasatinib-resistance in CML	763	763	0
chr9:5073770	G	T	V617F  myeloproliferative disorder diagnosis JAK2 inhibitor responsiveness	626	626	0
chr9:80409488	A	T	GNAQ Q209L Uveal melanoma hotspot 	569	568	0
chr9:80409488	A	C	GNAQ Q209P Uveal melanoma hotspot 	569	568	1
chr9:80409488	T	G	GNAQ Q209P Uveal melanoma hotspot 	569	568	0
